Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Evaluation of Allostatic Load as a Mediator of Sleep and Kidney Outcomes in Black Americans.

Lunyera J, Davenport CA, Jackson CL, Johnson DA, Bhavsar NA, Sims M, Scialla JJ, Stanifer JW, Pendergast J, McMullan CJ, Ricardo AC, Boulware LE, Diamantidis CJ.

Kidney Int Rep. 2018 Dec 18;4(3):425-433. doi: 10.1016/j.ekir.2018.12.005. eCollection 2019 Mar.

2.

Complements from the Lung.

Downing NS, McMullan CJ, Rennke HG, Levy BD, Loscalzo J.

N Engl J Med. 2018 Nov 1;379(18):1767-1773. doi: 10.1056/NEJMcps1802644. No abstract available.

PMID:
30380383
3.

Chronic Insufficient Sleep Has a Limited Impact on Circadian Rhythmicity of Subjective Hunger and Awakening Fasted Metabolic Hormones.

McHill AW, Hull JT, McMullan CJ, Klerman EB.

Front Endocrinol (Lausanne). 2018 Jun 12;9:319. doi: 10.3389/fendo.2018.00319. eCollection 2018.

4.

Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD.

Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS.

Am J Kidney Dis. 2018 Mar;71(3):362-370. doi: 10.1053/j.ajkd.2017.08.017. Epub 2017 Nov 11.

5.

Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial.

McMullan CJ, Borgi L, Fisher N, Curhan G, Forman J.

Clin J Am Soc Nephrol. 2017 May 8;12(5):807-816. doi: 10.2215/CJN.10771016. Epub 2017 Mar 20.

6.

The effect of vitamin D on renin-angiotensin system activation and blood pressure: a randomized control trial.

McMullan CJ, Borgi L, Curhan GC, Fisher N, Forman JP.

J Hypertens. 2017 Apr;35(4):822-829. doi: 10.1097/HJH.0000000000001220.

7.

A nested case-control study of the association between melatonin secretion and incident myocardial infarction.

McMullan CJ, Rimm EB, Schernhammer ES, Forman JP.

Heart. 2017 May;103(9):694-701. doi: 10.1136/heartjnl-2016-310098. Epub 2016 Nov 2.

PMID:
27806988
8.

Association of short sleep duration and rapid decline in renal function.

McMullan CJ, Curhan GC, Forman JP.

Kidney Int. 2016 Jun;89(6):1324-30. doi: 10.1016/j.kint.2015.12.048. Epub 2016 Mar 25.

9.

Finding a Signal in the Noise.

McMullan CJ, Forman JP.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):374-6. doi: 10.2215/CJN.00880116. Epub 2016 Feb 18. No abstract available.

10.

Prospective analysis of the association of ambulatory blood pressure characteristics with incident chronic kidney disease.

McMullan CJ, Hickson DA, Taylor HA, Forman JP.

J Hypertens. 2015 Sep;33(9):1939-46; discussion 1946. doi: 10.1097/HJH.0000000000000638.

PMID:
26066645
11.

Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease.

McMullan CJ, Yano Y, Bakris GL, Kario K, Phillips RA, Forman JP.

J Am Soc Hypertens. 2015 Apr;9(4):299-306. doi: 10.1016/j.jash.2015.02.005. Epub 2015 Feb 12.

PMID:
25891362
12.

Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.

McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D.

Am J Kidney Dis. 2014 Nov;64(5):714-22. doi: 10.1053/j.ajkd.2014.06.008. Epub 2014 Jul 24.

PMID:
25064674
13.

Myocardial extracellular volume expansion and the risk of recurrent atrial fibrillation after pulmonary vein isolation.

Neilan TG, Mongeon FP, Shah RV, Coelho-Filho O, Abbasi SA, Dodson JA, McMullan CJ, Heydari B, Michaud GF, John RM, Blankstein R, Jerosch-Herold M, Kwong RY.

JACC Cardiovasc Imaging. 2014 Jan;7(1):1-11. doi: 10.1016/j.jcmg.2013.08.013. Epub 2013 Nov 27.

14.

The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation .

Neilan TG, Shah RV, Abbasi SA, Farhad H, Groarke JD, Dodson JA, Coelho-Filho O, McMullan CJ, Heydari B, Michaud GF, John RM, van der Geest R, Steigner ML, Blankstein R, Jerosch-Herold M, Kwong RY.

J Am Coll Cardiol. 2013 Dec 10;62(23):2205-14. doi: 10.1016/j.jacc.2013.07.067. Epub 2013 Aug 28.

15.

Melatonin level and risk for type 2 diabetes--in reply.

McMullan CJ, Schernhammer ES, Forman JP.

JAMA. 2013 Aug 7;310(5):537. doi: 10.1001/jama.2013.7655. No abstract available.

PMID:
23925631
16.

Association of nocturnal melatonin secretion with insulin resistance in nondiabetic young women.

McMullan CJ, Curhan GC, Schernhammer ES, Forman JP.

Am J Epidemiol. 2013 Jul 15;178(2):231-8. doi: 10.1093/aje/kws470. Epub 2013 Jun 28.

17.

Melatonin secretion and the incidence of type 2 diabetes.

McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, Forman JP.

JAMA. 2013 Apr 3;309(13):1388-96. doi: 10.1001/jama.2013.2710.

18.

Association of BP variability with mortality among African Americans with CKD.

McMullan CJ, Bakris GL, Phillips RA, Forman JP.

Clin J Am Soc Nephrol. 2013 May;8(5):731-8. doi: 10.2215/CJN.10131012. Epub 2013 Mar 14.

19.

Race, plasma renin activity, and morning blood pressure surge--results from the Dietary Approaches to Stop Hypertension trial.

Mc Causland FR, McMullan CJ, Sacks FM, Forman JP.

Am J Hypertens. 2014 Apr;27(4):530-6. doi: 10.1093/ajh/hpt031. Epub 2013 Mar 8.

20.

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.

Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KC.

Cancer Res. 2008 Jul 1;68(13):5216-25. doi: 10.1158/0008-5472.CAN-07-5725.

21.

Antimyeloma activity of heat shock protein-90 inhibition.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC.

Blood. 2006 Feb 1;107(3):1092-100. Epub 2005 Oct 18.

22.

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL.

Cancer Cell. 2004 Mar;5(3):221-30.

23.

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC.

Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5. Epub 2003 Dec 26.

Supplemental Content

Loading ...
Support Center